For women diagnosed with advanced HER2-positive breast cancer, the spread of the disease to the brain and surrounding tissues – known as leptomeningeal metastases – has historically presented a devastating prognosis. These relatively rare, but aggressive, metastases often lead to rapid neurological decline, leaving patients with limited treatment options. But a new study offers a glimmer of hope, demonstrating a significant improvement in survival rates with a novel combination therapy.
Researchers at MD Anderson Cancer Center in Houston, Texas, evaluated a three-drug regimen in 17 women with HER2-positive breast cancer who had developed leptomeningeal metastases. The initial findings, published recently, are prompting cautious optimism within the oncology community. The study focuses on a particularly challenging scenario where cancer cells spread to the cerebrospinal fluid, coating the delicate membranes surrounding the brain and spinal cord. This differs from a localized brain tumor, as the disease is diffuse and can manifest as headaches, balance problems, partial paralysis, or even seizures, as explained by Doctissimo.
The Challenge of Treating Leptomeningeal Metastases
Treating leptomeningeal metastases is notoriously hard. The blood-brain barrier, a protective mechanism, often prevents many systemic drugs from reaching the cerebrospinal fluid in sufficient concentrations. Historically, treatment options have been largely limited to radiation therapy or direct injections of medication into the spinal fluid – procedures that carry their own risks and limitations. Tucatinib, a targeted therapy that inhibits the HER2 protein, had previously shown promise in treating brain metastases, and researchers noted its ability to penetrate the cerebrospinal fluid at levels comparable to those found in the bloodstream.
A Promising Combination for Extended Survival
The phase II TBCRC049 trial, a non-randomized study, involved 17 women, all at least 18 years old, with metastatic HER2-positive breast cancer and newly diagnosed leptomeningeal metastases. Participants received 21-day cycles of tucatinib twice daily, oral capecitabine (Xeloda) for 14 days out of 21, and trastuzumab administered via infusion every three weeks – a standard treatment for HER2-positive breast cancer. Fifteen of the women were already experiencing neurological symptoms at the start of the trial.
The results were striking. The median overall survival reached 10 months, more than double the 4.4 months observed in historical data from similar patients. 41% of the women were still alive at 18 months. “The combination allowed for a clinically significant improvement in overall survival compared to historical controls,” stated Rashmi Murthy, an associate professor of breast medical oncology and the study’s lead author. “For these patients, who often face limited treatment options, our findings represent a step forward, offering new hope in how we treat and manage leptomeningeal metastases.”
Improvements in Neurological Symptoms and Manageable Side Effects
Beyond survival rates, the study also revealed improvements in neurological function. Of the 13 patients whose metastases were evaluated, five showed an objective response. Seven out of 12 women who were followed for neurological deficits experienced an improvement in their symptoms. “In addition to the encouraging survival results, we observed improvements in neurological symptoms throughout the study,” explained Barbara O’Brien, an associate professor of neuro-oncology and co-lead author. “Historically, treatments for leptomeningeal metastases of breast cancer have focused on stabilizing the disease rather than improving symptoms, which makes these findings particularly meaningful and encouraging,” according to the MD Anderson Cancer Center.
The most common side effects – diarrhea, nausea, vomiting, hand-foot syndrome, and elevated liver enzymes – were generally considered manageable within the context of this limited trial involving 17 patients. While the study’s small sample size and early termination due to leisurely enrollment are limitations, the findings offer a crucial first step toward a more effective treatment approach for this challenging condition.
Understanding HER2-Positive Breast Cancer
HER2-positive breast cancer is a subtype of breast cancer characterized by the overproduction of the HER2 protein. This protein promotes cancer cell growth. According to the National Cancer Institute, approximately 20% of breast cancers are HER2-positive. Targeted therapies like trastuzumab and tucatinib are designed to block the HER2 protein, slowing or stopping cancer growth. The development of these therapies has significantly improved outcomes for patients with HER2-positive breast cancer, but leptomeningeal metastases remain a particularly difficult complication.
The research team acknowledges the need for larger, randomized clinical trials to confirm these findings and further refine the treatment regimen. However, the current data provides a much-needed signal of efficacy and a renewed sense of hope for women facing this devastating diagnosis. The next step will be to explore this combination therapy in a larger patient population and investigate potential biomarkers that could predict which patients are most likely to benefit from this approach.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
This research represents a significant advancement in the fight against leptomeningeal metastases from HER2-positive breast cancer. If you or someone you recognize is affected by breast cancer, please consider sharing this information and engaging in conversations with your healthcare provider about the latest treatment options.
Worth a look
